Molecular pathway activation features linked with transition from normal skin to primary and metastatic melanomas in human

Oncotarget

Volumn 7, Issue 1, 2016, Pages 656-670

  Shepelin, Denis ^a,b   Korzinkin, Mikhail ^a,c   Vanyushina, Anna ^d   Aliper, Alexander ^d   Borisov, Nicolas ^c,e   Vasilov, Raif ^e   Zhukov, Nikolay ^c,f   Sokov, Dmitry ^g   Prassolov, Vladimir ^h   Gaifullin, Nurshat ⁱ   Zhavoronkov, Alex ^j   Bhullar, Bhupinder ^k   Buzdin, Anton ^a,d,e  

^a Pathway Pharmaceuticals   (Hong Kong)

^b SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^c First Oncology Research and Advisory Centre   (Russian Federation)

^d Clinical Center of Pediatric Hematology Oncology and Immunology   (Russian Federation)

^e KURCHATOV INSTITUTE   (Russian Federation)

^f PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^g Moscow Oncological Hospital No 62   (Russian Federation)

^h ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

ⁱ MOSCOW STATE UNIVERSITY   (Russian Federation)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Intracellular molecular networks; Machine learning algorithms; Metabolic and signaling pathways; OncoFinder; Transition from nevus to primary and metastatic melanoma

Indexed keywords

BREXANOLONE; CARNITINE; FRUCTOSE; MYOINOSITOL HEXAKISPHOSPHATE; PHOSPHATE; RESOLVIN D; UNCLASSIFIED DRUG; ZYMOSTEROL; TRANSCRIPTOME;

ALGORITHM; ARTICLE; BIOINFORMATICS; BIOSYNTHESIS; CONTROLLED STUDY; DEPHOSPHORYLATION; DISEASE ASSOCIATION; DISEASE COURSE; HIGH THROUGHPUT SCREENING; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; MACHINE LEARNING; MELANOMA; METABOLITE; METASTATIC MELANOMA; NEVUS; PRIMARY TUMOR; SIGNAL TRANSDUCTION; SKIN; TRANSCRIPTOMICS; BIOLOGY; CELL TRANSFORMATION; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; SKIN TUMOR;

ALGORITHMS; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; HUMANS; MACHINE LEARNING; MELANOMA; METABOLIC NETWORKS AND PATHWAYS; NEOPLASM METASTASIS; PRINCIPAL COMPONENT ANALYSIS; SIGNAL TRANSDUCTION; SKIN; SKIN NEOPLASMS; TRANSCRIPTOME;

EID: 85011991674     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.6394     Document Type: Article

References (51)

1. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician. 2000; 62:357-68, 375-6, 381-2
2. Stewart BW, Wild C. International Agency for Research on Cancer, World Health Organization, editors. World cancer report 2014. Lyon, France: International Agency for Research on Cancer. 2014; 630
3. Ghissassi F El, Baan R, Straif K, Grosse Y, Secretan B, Bouvard V, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-part D: radiation. Lancet Oncol. 2009; 10:751-2
4. Greene MH. The genetics of hereditary melanoma and nevi. 1998 update. Cancer. 1999; 86:2464-77
5. Halachmi S, Gilchrest BA. Update on genetic events in the pathogenesis of melanoma. Curr Opin Oncol. 2001; 13:129-36
6. Davies MA, Samuels Y. Analysis of the genome to personalize therapy for melanoma. Oncogene. 2010; 29:5545-55
7. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012; 485:502-6
8. Campbell CD, Chong JX, Malig M, Ko A, Dumont BL, Han L, Vives L, O'Roak BJ, Sudmant PH, Shendure J, Abney M, Ober C, Eichler EE. Estimating the human mutation rate using autozygosity in a founder population. Nat Genet. 2012; 44:1277-81
9. Swope V, Alexander C, Starner R, Schwemberger S, Babcock G, Abdel-Malek ZA. Significance of the melanocortin 1 receptor in the DNA damage response of human melanocytes to ultraviolet radiation. Pigment Cell Melanoma Res. 2014; 27:601-10
10. Rodríguez CI, Setaluri V. Cyclic AMP (cAMP) signaling in melanocytes and melanoma. Arch Biochem Biophys. 2014; 563:22-7
11. Hartman ML, Czyz M. Pro-survival role of MITF in melanoma. J Invest Dermatol. 2015; 135:352-8
12. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA. Molecular basis of T cell inactivation by CTLA-4. Science. 1998; 282:2263-6
13. Ito A, Kondo S, Tada K, Kitano S. Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int. 2015; 2015:605478
14. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol. 2012; 8:e1002375
15. Khatri P, Draghici S. Ontological analysis of gene expression data: current tools, limitations, and open problems. Bioinformatics. 2005; 21:3587-95
16. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ. Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci USA. 2005; 102:13544-9
17. Mitrea C, Taghavi Z, Bokanizad B, Hanoudi S, Tagett R, Donato M, Voichita C, Draghici S. Methods and approaches in the topology-based analysis of biological pathways. Front Physiol. 2013; 4:278
18. Afsari B, Geman D, Fertig EJ. Learning dysregulated pathways in cancers from differential variability analysis. Cancer Inform. 2014; 13:61-7
19. Ho JWK, Stefani M, Remedios CG dos, Charleston MA. Differential variability analysis of gene expression and its application to human diseases. Bioinformatics. 2008; 24:i390-8
20. Eddy JA, Hood L, Price ND, Geman D. Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC). PLoS Comput Biol. 2010; 6:e1000792
21. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY, Borisov NM. Oncofinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front Genet. 2014; 5:55
22. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Roumiantsev SA, Aliper AM, Venkova LS, Smirnov PY, Borisov NM. The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis. Front Mol Biosci. 2014; 1:8
23. Borisov NM, Terekhanova NV, Aliper AM, Venkova LS, Smirnov PY, Roumiantsev S, Korzinkin MB, Zhavoronkov AA, Buzdin AA. Signaling pathways activation profiles make better markers of cancer than expression of individual genes. Oncotarget. 2014; 5:10198-205
24. Lezhnina K, Kovalchuk O, Zhavoronkov AA, Korzinkin MB, Zabolotneva AA, Shegay PV, Sokov DG, Gaifullin NM, Rusakov IG, Aliper AM, Roumiantsev SA, Alekseev BY, Borisov NM, et al. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget. 2014; 5:9022-32
25. Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A. Interactome analysis of myeloid-derived suppressor cells in murine models of colon and breast cancer. Oncotarget. 2014; 5:11345-53
26. Spirin PV, Lebedev TD, Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA, Dmitriev SE, Buzdin AA, Borisov NM, Aliper AM, Garazha AV, Rubtsov PM, Stocking C, et al. Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. Leukemia. 2014; 28:2222-8
27. Aliper AM, Csoka AB, Buzdin A, Jetka T, Roumiantsev S, Moskalev A, Zhavoronkov A. Signaling pathway activation drift during aging: Hutchinson-Gilford Progeria Syndrome fibroblasts are comparable to normal middle-age and old-age cells. Aging (Albany NY). 2015; 7:26-37
28. Makarev E, Cantor C, Zhavoronkov A, Buzdin A, Aliper A, Csoka AB. Pathway activation profiling reveals new insights into age-related macular degeneration and provides avenues for therapeutic interventions. Aging (Albany NY). 2014; 6:1064-75
29. Elder D. Tumor progression, early diagnosis and prognosis of melanoma. Acta Oncol. 1999; 38:535-47
30. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324:1029-33
31. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012; 2:881-98
32. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, Isenberg JS. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal. 2006; 8:1329-37
33. Roberts DD, Isenberg JS, Ridnour LA, Wink DA. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin Cancer Res. 2007; 13:795-8
34. Almeida A, Moncada S, Bolaños JP. Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat Cell Biol. 2004; 6:45-51
35. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, Wink DA. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA. 2004; 101:8894-9
36. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N. Arginine deprivation as a targeted therapy for cancer. Current pharmaceutical design. 2008; 14:1049
37. Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Guillen JM, Holubec H, Payne CM, Gerner EW. Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice. Mol Carcinog. 2006; 45:764-73
38. Gilmour SK. Polyamines and nonmelanoma skin cancer. Toxicol Appl Pharmacol. 2007; 224:249-56
39. Igarashi K, Sakamoto I, Goto N, Kashiwagi K, Honma R, Hirose S. Interaction between polyamines and nucleic acids or phospholipids. Arch Biochem Biophys. 1982; 219:438-43
40. Gerner EW, Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004; 4:781-92
41. Di Marino D, D'Annessa I, Tancredi H, Bagni C, Gallicchio E. A unique binding mode of the eukaryotic translation initiation factor 4E for guiding the design of novel peptide inhibitors. Protein Sci. 2015
42. Medina MA, Correa-Fiz F, Rodríguez-Caso C, Sánchez-Jiménez F. A comprehensive view of polyamine and histamine metabolism to the light of new technologies. J Cell Mol Med. 2005; 9:854-64
43. Abildgaard C, Guldberg P. Molecular drivers of cellular metabolic reprogramming in melanoma. Trends in Molecular Medicine. 2015; 21:164-71
44. van Vlies N, Ofman R, Wanders RJA, Vaz FM. Submitochondrial localization of 6-N-trimethyllysine dioxygenase-implications for carnitine biosynthesis. FEBS J. 2007; 274:5845-51
45. Monfregola J, Cevenini A, Terracciano A, van Vlies N, Arbucci S, Wanders RJA, D'Urso M, Vaz FM, Ursini MV. Functional analysis of TMLH variants and definition of domains required for catalytic activity and mitochondrial targeting. J Cell Physiol. 2005; 204:839-47
46. Wei YD, Rannug U, Rannug A. UV-induced CYP1A1 gene expression in human cells is mediated by tryptophan. Chem Biol Interact. 1999; 118:127-40
47. Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene. 2012; 31:776-86
48. Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK, Bührer C. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochemical and Biophysical Research Communications. 2008; 372:892-7
49. Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, Chen P-H, Li S, Fletcher AL, Yokoyama S, Scott KL, Garraway LA, Song JS, et al. Intronic miR-211 Assumes the Tumor Suppressive Function of Its Host Gene in Melanoma. Molecular Cell. 2010; 40:841-9
50. Mazar J, Khaitan D, DeBlasio D, Zhong C, Govindarajan SS, Kopanathi S, Zhang S, Ray A, Perera RJ. Epigenetic Regulation of MicroRNA Genes and the Role of miR-34b in Cell Invasion and Motility in Human Melanoma. PLoS ONE. 2011; 6:e24922
51. Shabalin AA, Tjelmeland H, Fan C, Perou CM, Nobel AB. Merging two gene-expression studies via cross-platform normalization. Bioinformatics. 2008; 24:1154-60